These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

192 related articles for article (PubMed ID: 21080009)

  • 21. Long-term safety and tolerability of rotigotine transdermal system in patients with early-stage idiopathic Parkinson's disease: a prospective, open-label extension study.
    Elmer LW; Surmann E; Boroojerdi B; Jankovic J
    Parkinsonism Relat Disord; 2012 Jun; 18(5):488-93. PubMed ID: 22326237
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Efficacy of Rotigotine at Different Stages of Parkinson's Disease Symptom Severity and Disability: A Post Hoc Analysis According to Baseline Hoehn and Yahr Stage.
    Giladi N; Nicholas AP; Asgharnejad M; Dohin E; Woltering F; Bauer L; Poewe W
    J Parkinsons Dis; 2016 Oct; 6(4):741-749. PubMed ID: 27567886
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Overnight switch from oral dopaminergic agonists to transdermal rotigotine patch in subjects with Parkinson disease.
    LeWitt PA; Boroojerdi B; MacMahon D; Patton J; Jankovic J
    Clin Neuropharmacol; 2007; 30(5):256-65. PubMed ID: 17909303
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Rotigotine may improve sleep architecture in Parkinson's disease: a double-blind, randomized, placebo-controlled polysomnographic study.
    Pierantozzi M; Placidi F; Liguori C; Albanese M; Imbriani P; Marciani MG; Mercuri NB; Stanzione P; Stefani A
    Sleep Med; 2016 May; 21():140-4. PubMed ID: 27448485
    [TBL] [Abstract][Full Text] [Related]  

  • 25. An observational clinical and video-polysomnographic study of the effects of rotigotine in sleep disorder in Parkinson's disease.
    Wang Y; Yang YC; Lan DM; Wu H-; Zhao ZX
    Sleep Breath; 2017 May; 21(2):319-325. PubMed ID: 27726069
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Daytime sleepiness may be an independent symptom unrelated to sleep quality in Parkinson's disease.
    Liguori C; Mercuri NB; Albanese M; Olivola E; Stefani A; Pierantozzi M
    J Neurol; 2019 Mar; 266(3):636-641. PubMed ID: 30607535
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Spotlight on rotigotine transdermal patch in Parkinson's disease.
    Sanford M; Scott LJ
    Drugs Aging; 2011 Dec; 28(12):1015-7. PubMed ID: 22117099
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Caregivers' and physicians' attitudes to rotigotine transdermal patch versus oral Parkinson's disease medication: an observational study.
    Sieb JP; Themann P; Warnecke T; Lauterbach T; Berkels R; Grieger F; Lorenzl S
    Curr Med Res Opin; 2015 May; 31(5):967-74. PubMed ID: 25772231
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Transdermal Patch of Rotigotine Attenuates Freezing of Gait in Patients with Parkinson's Disease: An Open-Label Comparative Study of Three Non-Ergot Dopamine Receptor Agonists.
    Ikeda K; Hirayama T; Takazawa T; Kawabe K; Iwasaki Y
    Intern Med; 2016; 55(19):2765-2769. PubMed ID: 27725534
    [TBL] [Abstract][Full Text] [Related]  

  • 30. A Randomized Controlled Exploratory Pilot Study to Evaluate the Effect of Rotigotine Transdermal Patch on Parkinson's Disease-Associated Chronic Pain.
    Rascol O; Zesiewicz T; Chaudhuri KR; Asgharnejad M; Surmann E; Dohin E; Nilius S; Bauer L
    J Clin Pharmacol; 2016 Jul; 56(7):852-61. PubMed ID: 26626320
    [TBL] [Abstract][Full Text] [Related]  

  • 31. A meta-analysis evaluating effects of the rotigotine in Parkinson's disease, focusing on sleep disturbances and activities of daily living.
    Sun W; Wang Q; Yang T; Feng C; Qu Y; Yang Y; Li C; Sun Z; Asakawa T
    Neurol Sci; 2022 Oct; 43(10):5821-5837. PubMed ID: 35691972
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Rotigotine Transdermal Patch: A Review in Parkinson's Disease.
    Frampton JE
    CNS Drugs; 2019 Jul; 33(7):707-718. PubMed ID: 31243728
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Impact of 6-month earlier versus postponed initiation of rotigotine on long-term outcome: post hoc analysis of patients with early Parkinson's disease with mild symptom severity.
    Timmermann L; Asgharnejad M; Boroojerdi B; Dohin E; Woltering F; Elmer LW
    Expert Opin Pharmacother; 2015; 16(10):1423-33. PubMed ID: 25997442
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Efficacy of pramipexole and transdermal rotigotine in advanced Parkinson's disease: a double-blind, double-dummy, randomised controlled trial.
    Poewe WH; Rascol O; Quinn N; Tolosa E; Oertel WH; Martignoni E; Rupp M; Boroojerdi B;
    Lancet Neurol; 2007 Jun; 6(6):513-20. PubMed ID: 17509486
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Switch from oral pramipexole or ropinirole to rotigotine transdermal system in advanced Parkinson's disease: an open-label study.
    Chung SJ; Kim JM; Kim JW; Jeon BS; Singh P; Thierfelder S; Ikeda J; Bauer L;
    Expert Opin Pharmacother; 2015 May; 16(7):961-70. PubMed ID: 25846031
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Rotigotine transdermal system for the treatment of Parkinson's disease.
    Pham DQ; Nogid A
    Clin Ther; 2008 May; 30(5):813-24. PubMed ID: 18555929
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Rotigotine: transdermal dopamine agonist treatment of Parkinson's disease and restless legs syndrome.
    Splinter MY
    Ann Pharmacother; 2007 Feb; 41(2):285-95. PubMed ID: 17213296
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Continuous transdermal dopaminergic stimulation in advanced Parkinson's disease.
    Metman LV; Gillespie M; Farmer C; Bibbiani F; Konitsiotis S; Morris M; Shill H; Bara-Jimenez W; Mouradian MM; Chase TN
    Clin Neuropharmacol; 2001; 24(3):163-9. PubMed ID: 11391128
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Transdermal rotigotine in advanced Parkinson's disease: a randomized, double-blind, placebo-controlled trial.
    Nomoto M; Mizuno Y; Kondo T; Hasegawa K; Murata M; Takeuchi M; Ikeda J; Tomida T; Hattori N
    J Neurol; 2014 Oct; 261(10):1887-93. PubMed ID: 25022939
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Outcomes of rotigotine clinical trials: effects on motor and nonmotor symptoms of Parkinson's disease.
    Lyons KE; Pahwa R
    Neurol Clin; 2013 Aug; 31(3 Suppl):S51-9. PubMed ID: 23931954
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.